During November 11 - 14, 2024, MEDICA 2024 witnessed the debut of Zybio’s EXZ 8000 Automated Hematology Analyzer and EXP 960 Quantitative Real-time PCR System as well as Zybio’s flagships of Core Lab Solution and Precision Diagnostic Solution based on 8 product lines, such as EXS 2600 MALDI-TOF Analyzer. 

Constant Innovation and Upgrading

Following the launch of MOCAP coagulation analyzers in April, 2024, another two new analyzers developed by Zybio have been launched this year and made their debut in MEDICA 2024. 

With next generation nucleic acid fluorescent dye platforms, EXZ 8000 Automated Hematology Analyzer features higher accuracy and realizes 120 samples/h throughput with flexible combo test of CBC + DIFF + NRBC + RET. EXZ 8000 supports automatic counting and classification of body fluid sample as well as automatic low-value WBC and PLT detection. 

EXP 960, the newly launched Quantitative Real-time PCR System, upgrades to 6 fluorescent channels to support the majority kits in market and 96 sample positions to support high detection efficiency. With average heating rage higher than 6.5°C/s, fast temperature system is supported.

Flagships Based on Recognized Technologies

Up to 2024, Zybio has over 100 invention patents, reference measurement procedures of 7 enzymology items in JCTLM database, 17 items accredited by CNAS. We are the first company in China to master MALDI-TOF technique and our microbiology mass spectrometry technique has obtained China Patent Excellence Award. 

The MALDI-TOF analyzer EXS 2600 ranks first in annual installations nationwide, and it is also well-received globally, such as in Turkey, the Czech Republic, Poland, Austria, Croatia, Serbia, Thailand, Indonesia, etc. Zybio holds 32 patents for our MALDI-TOF and the system includes a database of over 4,000 local microbial species. Besides in clinical labs, EXS 2600 has been also widely applied in research filed for ongoing research and publications. Up to now, multiple essays in microbiology-related journals have proved its excellent performance in fungi identification and confusing microbial differentiation. Furthermore, Zybio is working on expanding the mass spectrometry products to include nucleic acid mass spectrometry for more precise detection of genetic markers and a triple quadrupole system for applications like amino acids, newborn screening and drug development. 

Since the launch of Automated Coagulation Analyzers based on MOCAP (Mechanical and Optical Coagulation Analysis Platform), the coagulation analyzers YX-3000/2000 have gained major focus and recognition. Beside the U.S. patent for MOCAP technology was issued in 2021, Zybio’s coagulation platform obtained another three patents in 2024 respectively from authorities in U.S., Europe and China. 

MOCAP enables coagulation detection unaffected by HIL (hemolysis, icterus, lipemia) with lower consumable costs based on automatic switch between optical and mechanical coagulation detecting methods according to sample status. Furthermore, the integration of optical-mechanical methods in one analyzer avoids inconsistent test results between different analyzers. 

Since 2018 when we started overseas business, Zybio has gradually set up offices in multiple countries and regions, as well as subsidiaries in Indonesia, Thailand, Philippines, Brazil, Mexico, Pakistan, Russia, Netherlands, etc. Currently, Zybio has over 300 engineers worldwide for an integrated Sales & Service system. The products, diagnostic solutions and services have been widely applied in over 20,000 healthcare facilities in 100 countries and regions in Asia, South America, North America, Europe and Africa. 

Dedication to Accuracy, Zybio has been and will always be committed to improvement of total laboratory diagnostic solution and increasingly excellent products and services for partners. In this way, we aim to jointly facilitate the healthcare industry.